P1/2, N=210, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | N=96 --> 210 | Trial completion date: Mar 2028 --> Mar 2029 | Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2026 --> Mar 2027

Nectin-4 expression in the prostate is heterogeneous and context-dependent, with higher levels in benign glands within cancer-bearing prostates and lower levels with advancing tumor stage and nodal/metastatic spread. These findings provide an expression map of nectin 4 across benign and malignant prostate compartments and disease stages and may inform future exploratory enrichment strategies for nectin-4-targeted therapies.

Personalized, tumor-informed ctDNA testing can indicate response to EV±P and is prognostic of survival benefit in patients with la/mUC receiving EV±P.

P2, N=348, Not yet recruiting, Akeso

P1/2, N=27, Not yet recruiting, Fred Hutchinson Cancer Center

P1/2, N=78, Not yet recruiting, Astellas Pharma Global Development Inc.

P2, N=56, Not yet recruiting, The Netherlands Cancer Institute

P1, N=294, Not yet recruiting, Shandong New Time Pharmaceutical Co., LTD

P2, N=58, Recruiting, Peking University Third Hospital

We describe a 57-year-old man receiving EV and pembrolizumab who developed profound insulin-resistant DKA that persisted despite standard therapy. Following initiation of induction alongside continued insulin therapy, resolution of ketoacidosis occurred within 46 hours. This case illustrates a pharmacokinetic-informed approach to EV-associated refractory DKA and highlights how understanding drug metabolism may improve therapeutic outcomes when conventional therapy is insufficient.

P2, N=39, Not yet recruiting, University of Florida